MedPath

EirGenix, Inc.

EirGenix, Inc. logo
🇹🇼Taiwan
Ownership
Public
Established
2012-01-01
Employees
51
Market Cap
-
Website
http://www.eirgenix.com

Clinical Trials

6

Active:2
Completed:3

Trial Phases

2 Phases

Phase 1:2
Phase 3:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 3
4 (66.7%)
Phase 1
2 (33.3%)

Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.

Phase 3
Not yet recruiting
Conditions
Early Breast Cancer
Interventions
Drug: EG1206A
First Posted Date
2025-03-25
Last Posted Date
2025-04-03
Lead Sponsor
EirGenix, Inc.
Target Recruit Count
380
Registration Number
NCT06884254
Locations
🇺🇸

Methodist Health System Clinical Research Institute, Dallas, Texas, United States

A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers

Phase 1
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2022-07-25
Last Posted Date
2023-01-26
Lead Sponsor
EirGenix, Inc.
Target Recruit Count
135
Registration Number
NCT05471648
Locations
🇩🇪

CRS Clinical Research Services Berlin GmbH, Berlin, Germany

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2018-02-14
Last Posted Date
2023-01-20
Lead Sponsor
EirGenix, Inc.
Target Recruit Count
807
Registration Number
NCT03433313
Locations
🇺🇸

Detroit Clinical Research Center, Farmington Hills, Michigan, United States

🇺🇸

Aultman Hospital, Cancer Center, Canton, Ohio, United States

🇧🇾

Brest Regional Oncology Center, Brest, Belarus

and more 86 locations

A Pharmacokinetic Study Comparing EG12014 and Herceptin (Trastuzumab) in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
First Posted Date
2017-06-08
Last Posted Date
2017-06-08
Lead Sponsor
EirGenix, Inc.
Target Recruit Count
84
Registration Number
NCT03180242

News

No news found
© Copyright 2025. All Rights Reserved by MedPath